KRSA Stock Forecast: Korsana Biosciences, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Korsana Biosciences, Inc. hold a median 12-month price target of $44 — +15.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Korsana Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KRSA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KRSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Wells Fargo | Initiates | Overweight | $44 |
| 5 Oct 2026 | Wedbush | Initiates | Outperform | $44 |
| 28 Sept 2026 | Guggenheim | Initiates | Buy | $70 |
| 14 Sept 2026 | Stifel | Initiates | Buy | $43 |
| 14 Sept 2026 | TD Cowen | Initiates | Buy | — |
| 11 Sept 2026 | UBS | Initiates | Buy | $55 |
| 20 Oct 2021 | Truist Securities | Initiates | Buy | $14 |
| 24 Sept 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KRSA.
This page is one stock. Monday covers all of them.
KRSA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KRSA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Korsana Biosciences, Inc. returned +282.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KRSA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.9×
- EV / EBITDA
- —
Cheaper than 31% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- —
- Return on assets
- −23.1%
- Dividend yield
- —
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Korsana Biosciences, Inc. has a market value of $1.7B and an enterprise value of $267.8M.
Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$6.7M, a −353.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$4.5M.
Korsana Biosciences, Inc. employs 19 people — $100K of revenue per employee.
Data provided by Twelve Data
KRSA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KRSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Korsana Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KRSA
What is the KRSA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Korsana Biosciences, Inc. have a median 12-month price target of $44, with estimates ranging from $8 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KRSA stock a buy right now?
Of the 6 analysts covering Korsana Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Korsana Biosciences, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KRSA?
As at 21 Nov 2026, Korsana Biosciences, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
Will KRSA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +15.9% from the last close, and Ticker Nerd's factor model ranks Korsana Biosciences, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KRSA stock forecast for 2030?
No analyst covering Korsana Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $70 over the next 12 months.
How has KRSA stock performed over the past year?
Korsana Biosciences, Inc. returned +282.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Korsana Biosciences, Inc. do?
Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease. Its work centers on THETA, a proprietary blood-brain barrier shuttle platform designed to improve delivery of large therapeutic molecules into the central nervous system.
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease. Its work centers on THETA, a proprietary blood-brain barrier shuttle platform designed to improve delivery of large therapeutic molecules into the central nervous system. The company’s current pipeline includes THETA-enabled antibody programs aimed at addressing disease biology in the brain, including an anti-amyloid beta approach for Alzheimer’s disease. Korsana Biosciences operates in the health care and life sciences sector, where its role is to advance precision-engineered biologics for central nervous system disorders. The company is based in Waltham, Massachusetts.
CEO Dr. Jonathan Violin M.B.A., Ph.D. · 19 employees · United States · https://korsana.com